Elis Pharma Introduces Erectile Dysfunction Drug, Vitaros(R) Licensed From Apricus Biosciences at Major Pharmaceutical Conference in Dubai
Elis Pharmaceuticals Limited
09.03.2012 18:50
---------------------------------------------------------------------------
The Presentation is Part of Elis Pre-Launch Marketing Strategy for the Drug
Licensed From Apricus Biosciences
DUBAI, United Arab Emirates, 2012-03-09 18:50 CET (GLOBE NEWSWIRE) --
Elis Pharmaceuticals (www.elispharmaceuticals.com), announced today that the
company would present Vitaros(r) at the Dubai International Pharmaceuticals and
Technologies Conference and Exhibition (DUPHAT), which will be held 12-14 March
2012 (http://www.duphat.ae) as part of its pre-launch strategy.
Vitaros(r) is a drug for erectile dysfunction (ED) that Elis licensed from
Apricus Biosciences (Nasdaq:APRI) (www.apricusbio.com) in January of 2011,
having exclusive rights to sell the drug in the Gulf Countries and part of the
Middle East. 'We believe that Vitaros(r) will be an important new first line
therapy for ED in our region,' explained Rashed Assouma, Chief Executive
Officer of Elis. 'Since DUPHAT is the most significant pharmaceutical event in
the Middle East and North Africa, it offers the best opportunity for us to
introduce the drug.'
At DUPHAT, Elis will present Vitaros(r) to pharmacists, pharmaceutical
professionals, key decision makers and government heads and officials from the
Middle East, Africa and Commonwealth of Independent States countries. The
presentation combined with patient responses observed in this population is the
first step in the marketing campaign that Elis plans for Vitaros(r) once the drug
is approved in the region.
'Because of Elis' proven marketing strategies and the patient responses we've
already experienced as part of our sampling program, we anticipate strong sales
of Vitaros(r) in this region, where the total market for erectile dysfunction
drugs is more than $100 million per year,' continued Mr. Assouma.
Vitaros(r) was approved by Health Canada in November 2010 as the first topical
treatment for erectile dysfunction ('ED') for marketing in Canada. This
validation also made it possible to register the drug in other countries that
recognize Canadian approval. The application for approval to market Vitaros(r) in
the territory licensed to Elis was filed in the first half of 2011, with final
approval expected by the end of 2012.
Despite the availability of today's oral and other therapies, there is still a
need for new, safe and effective treatments, especially for those patients who
cannot or do not respond well to oral medication. One key advantage of Vitaros(r)
is that it is applied directly to the penis as a cream, instead of as a pill
that is absorbed systemically. The topical application helps to minimize side
effects and enables men who cannot take, or do not do well with the existing
drugs, to have a patient-friendly alternative.
About Elis Pharmaceuticals Limited
Established in the UAE, Elis Pharmaceuticals is one of the region's leading
companies dedicated to developing, manufacturing and marketing prescription and
generic pharmaceuticals. The Company markets and distributes products in three
main categories: prescription medications, OTC and generics. With over 100
pharmaceutical products in its portfolio, Elis Pharma is uniquely poised to
maximize the market potential of emerging products and is the likely choice for
commercializing and marketing any new pharmaceutical products in its territory.
The company serves drug wholesalers, distributors of pharmaceuticals,
ministries and departments of health; public, private, industry and military
hospitals, clinics and healthcare systems and affiliated organizations
worldwide. For further information on Elis Pharma and its subsidiaries, visit
http://www.elispharmaceuticals.com.
CONTACT: Elis Pharmaceuticals
Abdul-Khaleq Osman
Public Relations
+9714 2653 844
pr@elispharmaceuticals.com
News Source: NASDAQ OMX
09.03.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Elis Pharmaceuticals Limited
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901938079
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Elis Pharmaceuticals Limited
09.03.2012 18:50
---------------------------------------------------------------------------
The Presentation is Part of Elis Pre-Launch Marketing Strategy for the Drug
Licensed From Apricus Biosciences
DUBAI, United Arab Emirates, 2012-03-09 18:50 CET (GLOBE NEWSWIRE) --
Elis Pharmaceuticals (www.elispharmaceuticals.com), announced today that the
company would present Vitaros(r) at the Dubai International Pharmaceuticals and
Technologies Conference and Exhibition (DUPHAT), which will be held 12-14 March
2012 (http://www.duphat.ae) as part of its pre-launch strategy.
Vitaros(r) is a drug for erectile dysfunction (ED) that Elis licensed from
Apricus Biosciences (Nasdaq:APRI) (www.apricusbio.com) in January of 2011,
having exclusive rights to sell the drug in the Gulf Countries and part of the
Middle East. 'We believe that Vitaros(r) will be an important new first line
therapy for ED in our region,' explained Rashed Assouma, Chief Executive
Officer of Elis. 'Since DUPHAT is the most significant pharmaceutical event in
the Middle East and North Africa, it offers the best opportunity for us to
introduce the drug.'
At DUPHAT, Elis will present Vitaros(r) to pharmacists, pharmaceutical
professionals, key decision makers and government heads and officials from the
Middle East, Africa and Commonwealth of Independent States countries. The
presentation combined with patient responses observed in this population is the
first step in the marketing campaign that Elis plans for Vitaros(r) once the drug
is approved in the region.
'Because of Elis' proven marketing strategies and the patient responses we've
already experienced as part of our sampling program, we anticipate strong sales
of Vitaros(r) in this region, where the total market for erectile dysfunction
drugs is more than $100 million per year,' continued Mr. Assouma.
Vitaros(r) was approved by Health Canada in November 2010 as the first topical
treatment for erectile dysfunction ('ED') for marketing in Canada. This
validation also made it possible to register the drug in other countries that
recognize Canadian approval. The application for approval to market Vitaros(r) in
the territory licensed to Elis was filed in the first half of 2011, with final
approval expected by the end of 2012.
Despite the availability of today's oral and other therapies, there is still a
need for new, safe and effective treatments, especially for those patients who
cannot or do not respond well to oral medication. One key advantage of Vitaros(r)
is that it is applied directly to the penis as a cream, instead of as a pill
that is absorbed systemically. The topical application helps to minimize side
effects and enables men who cannot take, or do not do well with the existing
drugs, to have a patient-friendly alternative.
About Elis Pharmaceuticals Limited
Established in the UAE, Elis Pharmaceuticals is one of the region's leading
companies dedicated to developing, manufacturing and marketing prescription and
generic pharmaceuticals. The Company markets and distributes products in three
main categories: prescription medications, OTC and generics. With over 100
pharmaceutical products in its portfolio, Elis Pharma is uniquely poised to
maximize the market potential of emerging products and is the likely choice for
commercializing and marketing any new pharmaceutical products in its territory.
The company serves drug wholesalers, distributors of pharmaceuticals,
ministries and departments of health; public, private, industry and military
hospitals, clinics and healthcare systems and affiliated organizations
worldwide. For further information on Elis Pharma and its subsidiaries, visit
http://www.elispharmaceuticals.com.
CONTACT: Elis Pharmaceuticals
Abdul-Khaleq Osman
Public Relations
+9714 2653 844
pr@elispharmaceuticals.com
News Source: NASDAQ OMX
09.03.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Elis Pharmaceuticals Limited
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901938079
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------